Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Ain Shams University, Cairo
Patients with chronic hepatitis C genotype 4 respond to therapy earlier
July 6th, 2005
Patients with chronic hepatitis C genotype 4 respond to therapy earlier. According to recent research from Egypt, "the response rates and duration of peginterferon alpha (PEG-IFN-alpha) and ribavirin combination therapy in chronic hepatitis C genotype 4, the prevalent genotype in the Middle East and Africa, are poorly documented." S.M. Kamal and colleagues, Ain Shams Faculty Medicine, conducted a study "to compare the efficacy and safety of 24, 36, or 48 weeks of PEG-IFN-alpha-2b and ribavirin therapy in chronic hepatitis C genotype 4." "In this prospective, randomized, double blind study, 287 patients with chronic hepatitis C...
Source: Biotech Week (2005-07-06)
|
